Phase 1 Data Position CLYM116 as a Best-in-Class APRIL Suppressor with Q12W Dosing Potential
CLYM has more than doubled off its 52-week low of $1.54.
Summary
Positive Phase 1 data for CLYM116 show a prolonged half-life and deep, durable APRIL suppression, supporting every-12-week dosing in IgA nephropathy.
Key Events · Product Development and Regulatory · CLYM
-
Phase 1 Data Exceeds Target
A single 320 mg SC dose of CLYM116 achieved >90% free APRIL suppression and 60-75% reductions in IgA, Gd-IgA1, and IgM maintained through 12 weeks in 46 healthy volunteers.
-
Best-in-Class Half-Life
The projected ~29-day half-life is approximately 3x longer than sibeprenlimab's 9.3 days, with linear clearance and no target-mediated drug disposition at doses ≥160 mg.
-
Q12W Dosing Regimen Defined
PK/PD modeling supports an 800 mg loading dose followed by 400 mg every 12 weeks—reducing injections from 12 to 4 annually versus first-generation anti-APRIL therapies.
-
Favorable Safety Profile
No serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia were observed; all AEs were mild-to-moderate and self-resolving.
Analysis · CLYM · Life Sciences
The Phase 1 results for CLYM116, an anti-APRIL antibody, suggest it could become a best-in-class treatment for IgA nephropathy. Its ~29-day half-life is three times longer than sibeprenlimab's, and a single 320 mg dose achieved >90% free APRIL suppression along with 60-75% reductions in IgA, Gd-IgA1, and IgM that were sustained through 12 weeks. This durability supports an every-12-week dosing schedule—a meaningful convenience advantage over once-monthly competitors. The data de-risk the ongoing NAVIGATE-2 Phase 2 trial and the planned Phase 3 initiation in 2027. For a company with a $864M market cap and a $239M cash runway into 2H 2028, these results validate the lead pipeline asset and strengthen the investment thesis.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLYM was trading at $16.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $864.4M. The 52-week trading range was $1.54 to $18.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.